Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of "Reduce" from Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) have been assigned an average recommendation of "Reduce" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $7.42.

Several equities research analysts recently issued reports on BHC shares. StockNews.com downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, Royal Bank of Canada upped their price target on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd.

Hedge Funds Weigh In On Bausch Health Companies

Several hedge funds have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Bausch Health Companies by 3.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company's stock worth $2,102,000 after buying an additional 9,834 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Bausch Health Companies by 97.1% during the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company's stock worth $6,136,000 after buying an additional 467,270 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Bausch Health Companies by 1,548.9% in the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company's stock worth $162,000 after acquiring an additional 23,451 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Bausch Health Companies during the 1st quarter worth $68,000. Finally, Cubist Systematic Strategies LLC lifted its position in Bausch Health Companies by 162.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 607,656 shares of the company's stock worth $3,933,000 after acquiring an additional 376,518 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Trading Up 0.6%

Shares of Bausch Health Companies stock opened at $4.67 on Wednesday. The stock has a 50-day moving average price of $5.46 and a 200 day moving average price of $6.91. The company has a market cap of $1.69 billion, a P/E ratio of -38.91, a P/E/G ratio of 0.37 and a beta of 0.34. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The business had revenue of $2.56 billion during the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, equities analysts forecast that Bausch Health Companies will post 4.41 earnings per share for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.